Towards the future of upper tract urothelial carcinoma surveillance: lessons learnt from bladder cancer urinary biomarkers
Gallioli: project development, data collection, and manuscript writing/editing. Boissier: data analysis and manuscript editing. Territo: data collection and management. Breda: project development and manuscript editing.
Compliance with ethical standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
After ethical committee approval, all patients enrolled in our study signed an informed consent.
Conflict of interest
All the authors declare that they have no potential conflicts of interest.
- 5.Witjes JA, Morote J, Cornel EB et al (2018) Performance of the Bladder EpiCheck™ Methylation Test for patients under surveillance for non–muscle-invasive bladder cancer: results of a multicenter, prospective, blinded clinical trial. Eur Urol Onc 1:307–313. https://doi.org/10.1016/j.euo.2018.06.011 CrossRefGoogle Scholar
- 8.Run-Qi G, Gen-Yan X, Kai-Wei Y et al (2018) Detection of urothelial carcinoma, upper tract urothelial carcinoma, bladder carcinoma, and urothelial carcinoma with gross hematuria using selected urine-DNA methylation biomarkers: a prospective, single-center study. Urol Oncol 36(7):342.e15–342.e23. https://doi.org/10.1016/j.urolonc.2018.04.001 CrossRefGoogle Scholar